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Combined effect of monoclonal antilipopolysaccharide
antibody and ceftazidime in intranasal mice model of
Klebsiella pneumoniae infection
Abstract
Background and Purpose: The evolution of microorganisms in the
sense of antimicrobial resistance is an emerging problem, especially in hos-
pital settings. It seriously complicates the ability to combat severe infections.
Bacteria of the genus Klebsiella are well known bacterial pathogens that
cause a wide variety of infections. Numerous recent articles have reported
the growing trend of antimicrobial resistance among clinical isolates of
Klebsiella. Besides capsular antigen the most important virulence factor of
genus Klebsiella is lipopolysaccharide (LPS). Therefore, previously gener-
ated antilipopolysaccharide monoclonal antibody for O1 antigen of Klebsi-
ella pneumoniae was used in this study. The purpose of this study was to ex-
amine the existence of synergy between antilipopolysaccharide monoclonal
antibody Ru-O1 (mAb Ru-O1) and ceftazidime in a model of lung Kleb-
siella infection.
Materials and Methods: The study was conducted using Klebsiella
pneumoniae strain Caroli (O1:K2) to inoculate BALB/c mice by intra-
nasal route. Mice were lethally infected with the bacteria. The effects of
mAb Ru-O1 and ceftazidime, as a single treatment protocol or in combina-
tion, were monitored on the survival of experimental animals.
Results: The overall survival rates in groups pretreated only with mAb
Ru-O1 prior to infection or treated only with ceftazidime 24 hours after in-
fection were 33%. The outcome of infection was best in a group of mice that
received both mAb and single dose of ceftazidime with overall survival rate
of 66%.
Conclusions: The study shows that the combination treatment with
anti-LPS mAb Ru-O1 and ceftazidime in a mice model of lethal Klebsiella
pneumoniae pneumonia exerts synergistic effect and enhances the survival
of experimental animals compared to animals treated with mAb Ru-O1 or
ceftazidime alone.
INTRODUCTION
Antimicrobial resistance is an ever increasing problem in everydaymedical practice. This issue is especially emphasized in hospital
settings where it may represent significant problem regarding the selec-
tion of efficient antimicrobial therapy for the treatment of severe and
sometimes life threatening infections such as bacterial pneumonia and
sepsis. Literature data suggest that improper and exaggerated adminis-
tration of antimicrobials contributes to the development of bacterial re-
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sistance (1, 2). On the other hand, considerable amount
of data suggest that health care environments with lim-
ited and more rational approach to antibiotic therapy are
characterized with lower rates of antibiotic resistant bac-
teria. Therefore, the limitation in antibiotic consump-
tion, according to some recommendations, may be bene-
ficial for slowing down antibiotic resistance development
(3, 4).
Pneumonia caused with Klebsiella pneumoniae (K.
pneumoniae) is a common infection in hospitalized pa-
tients. The clinical course of infection is often rapidly
progressive and may be complicated with the develop-
ment of sepsis and septic shock. These infections, even
with administration of proper antimicrobial agent, so-
metimes do not solve efficiently and are associated with
high mortality rates (5, 6). Situation is nowadays even
more serious because of the emergence of multidrug-re-
sistant Klebsiella strains. In many patients the delay in
resolution of infection, especially in immunocompro-
mised patients, results in even higher mortality.
The monoclonal antibody Ru-O1 (mAb Ru-O1) spe-
cific for O1 lipopolysaccharide (LPS) antigen of K. pneu-
moniae was previously described (7). The antibody was
shown to be protective in a model of experimental lethal
Klebsiella sepsis, resulting in considerable survival of an-
imals that were protected prior to lethal intraperitoneal
infection.
Some literature data suggest that the combination of
antibiotics with immunological preparations may con-
tribute to the better resolution and increased survival of
patients with severe bacterial infections (8, 9).
This study was performed to test the efficacy of mAb
Ru-O1 in a mouse model of lethal lung Klebsiella infec-
tion. Besides that, the goal of this study was to examine
whether the effect of mAb, that was expected, may be en-
hanced by administration of a single dose of antibiotic.
MATERIALS AND METHODS
Mice
BALB/c male mice were used in this study which
were obtained from the breeding colony of the Medical
Faculty, University of Rijeka. Eight to ten weeks old spe-
cific pathogen free mice were kept in plastic cages and
given standard laboratory food and water ad libitum.
The experiments were conducted according to the laws
and principles found in the International Guiding Prin-
ciples of Biomedical Research Involving Animals by the
Council of International Organisations of Medical Sci-
ence (10) and the corresponding legislation of the Re-
public of Croatia.
Bacteria
Experimental infections were preformed using a highly
virulent strain K. pneumoniae Caroli (O1:K2) that has
been used and described previously (7, 11, 12).
Bacteria were grown on blood agar plates for 18 hours
harvested and suspended in sterile saline solution. The
bacterial number was determined by spectrophotometric
analysis using measurement in the absorbance mode at
wavelength of 600 nm, which was confirmed by colony
counts on blood agar plates after serial 10-fold dilution.
The original bacterial suspension was adjusted spectro-
photometrically to a final concentration of 5x107 CFU/
mL. Bacterial inoculum was prepared from the original
suspension by the addition of the appropriate volume of
sterile saline and adjusted to contain 250 CFU of K.
pneumoniae Caroli in 25 µL.
Monoclonal antibody Ru-O1
Experiments were performed by using mAb Ru-O1
that was described previously (7). The antibody has shown
to be highly specific for the O1 antigen of Klebsiella and
to be protective in a model of lethal Klebsiella systemic
infection. The antibody was given in a dose of 1 mg per
mouse and was administered four hours prior to infec-
tion by intraperitoneal injection.
Antibiotic
For the treatment of experimental pneumonia, the
third generation cephalosporin ceftazidime (Mirocef, Pliva,
Zagreb, Croatia) was used, in a single dose of 80 mg/kg
according to standard therapeutic regimens. The antibi-
otic was administered by intraperitoneal injection.
Survival study – Determination of Ru-O1
mAb efficiency alone or in combination
with ceftazidime
Before the proposed experiments, the 50% lethal dose
(LD50) for the intranasal route of lung infection with K.
pneumoniae Caroli, was determined using the Reed and
Muench method (13). The animals were infected by
intranasal route of infection with 25 µL of bacterial sus-
pension. For inoculation, mice were briefly anesthetized
with ether. The bacterial inoculum was applied to the
nose tip of mouse with a pipette tip and involuntarily in-
haled by animals. Mice were held vertically for 2 minutes
after the inoculation. The animals were observed for 14
days, and mortality was recorded daily. The LD50 of K.
pneumoniae Caroli for the intranasal route of infection
was determined to be 50 CFU of bacteria per mouse
(data not shown).
To determine the efficiency of Ru-O1 mAb alone or in
combination with ceftazidime, a series of experiments
were conducted. The total number of 48 animals were
divided in 4 groups. Each group contained 12 animals.
The first group was designated as untreated, which
means that animals received neither antibody nor antibi-
otic. Four hours prior to infection those animals received
sterile saline solution intraperitoneally.
The pretreated group received antibody Ru-O1 by
intraperitoneal injection four hours prior to infection.
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The third group (antibiotic) received intraperitoneal-
ly single therapeutic dose (80 mg/kg) of ceftazidime 24
hours after the infection.
The last, fourth group (combination), was pretreated
with antibody four hours before the infection and was
treated with a single dose of ceftazidime 24 hours post in-
fection.
Bacterial counts in organs
To confirm the effectiveness of intranasal route of in-
fection and the establishment of lung infection, another
experiment was performed in order to determine bacte-
rial counts in different organs. The untreated experi-
mental group of ten animals was infected as described
above. Mice were divided in two subgroups of five ani-
mals. The first subgroup was sacrificed 24, and the sec-
ond 48 hours after the infection by inhalation of CO2 and
the blood was immediately obtained by cardiac punc-
ture. Livers, spleens, tracheas and lungs were aseptically
removed, dissected and homogenized in 5 ml of sterile
saline. Serial ten-fold dilutions of organ homogenates
were plated on the surface of blood agar plates, incubated
for 24 hours, colonies were counted and bacterial counts
in organs were calculated. It should be mentioned that
two of five animals in 48 hour subgroup succumbed to
infection. Therefore, the results that are presented for
that time point represent values obtained from the re-
maining three mice.
Statistical analysis
Survival of different groups was presented using Kap-
lan-Meier survival curves. Statistical comparison of sur-
vival curves between groups was performed by Logrank
test using MedCalc Statistical Software, version 9.2.1.0
(MedCalc Software, Belgium). Differences were consid-
ered statistically significant at p<0.05.
RESULTS
Survival study
After the infection of animals with 100% lethal dose of
K. pneumoniae strain Caroli, all mice in untreated group
died until the forth day post infection. The development
of lethal effect in these animals was very rapid in spite of
relatively low infectious dose, suggesting highly virulent
properties of the used bacterial strain. The overall sur-
vival rates in groups pretreated only with mAb Ru-O1
prior to infection or treated only with ceftazidime 24
hours after infection were 33%. However, there are mi-
nor differences between these groups since the animals
in the pretreated group died from infection between the
second and fourth day while animals in antibiotic group
succumbed to infection between the second and sixth
day after the infection. The outcome of infection was best
in the group of mice that received both mAb and cef-
tazidime with the overall survival rate of 66%. The statis-
tical comparison of survival curves revealed significant
differences of survival between animals from combina-
tion vs. untreated group (p<0.0001), combination vs.
pretreated group (p=0.0243), combination vs. antibiotic
group (p=0.0243), and antibiotic vs. untreated group
(p=0.0079). The survival was not statistically different
between pretreated vs. antibiotic group and between pre-
treated vs. untreated group of animals (Figure 1).
Bacterial counts in organs
The aim of this part of study was to confirm the effec-
tiveness of intranasal route of infection and the establish-
ment of lung infection. Therefore, the bacterial counts in
lungs and several other organs of infected animals that
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Figure 1. Survival of untreated group (–––), pretreated group with
mAb Ru-O1 (- - - -), antibiotic group (.......) and a combination group
of animals (- . - . -) lethally infected with K. pneumoniae Caroli.
TABLE 1
The bacterial counts in organs from untreated animals
24 hours post infection expressed as CFU per 1 mL of
organ homogenates.
Organ Median value Range
Trachea 8 x 102 6.9 x 102 – 8.8 x 102
Lung 4.3 x 103 1.1 x 103 – 4.9 x 103
Liver 4.4 x102 3.9 x 101 – 4.6 x 102
Spleen 1.8 x 102 1.1 x 102 – 2.1 x 102
Blood 1.1 x 104 8.4 x 103 – 1.4 x 104
TABLE 2
The bacterial counts in organs from untreated animals
48 hours post infection expressed as CFU per 1 mL of
organ homogenates.
Organ Median value Range
Trachea 1.5 x 105 7.1 x 104 – 1.8 x 105
Lung 6.5 x 104 2.1 x 104 – 7 x 104
Liver 9.7 x 104 4.1 x 104 – 1.2 x 105
Spleen 1.7 x 105 8.2 x 104 – 2.4 x 105
Blood 8 x 105 5.5 x 105 – 9.2 x 105
were treated neither with mAb Ru-O1 nor with cefta-
zidime were determined. The effectiveness of experi-
mental infection was obvious already 24 hours after the
infection, when in all analyzed organs and blood, bacte-
rial counts reached considerably higher values compared
with a relatively low number of bacteria that were used
for infection, e.g. 250 CFU per mice (Table 1). The re-
sults indicate that bacteria started to disseminate very
early during the course of infection resulting in high bac-
terial contents in all analyzed organs. During the follow-
ing 24 hours further increase in bacterial counts was de-
tected (Table 2). The continuous growth of bacterial
count during that period was associated with the begin-
ning of mortality in experimental animals.
DISCUSSION
Although significant advances in the therapy of bacte-
rial infections have been achieved in the last few decades,
some of these infections have still remained a significant
therapeutic problem, especially in hospitalized patients.
Infections like nosocomial pneumonia and sepsis are still
associated with high mortality rates (14, 15). Explana-
tions for such undesired outcomes may include rapidly
progressive nature of these infections, especially in im-
munocompromised patients, that often results in the late
onset of antimicrobial therapy. Additional important rea-
son may be the emerging bacterial resistance against
antimicrobial agents. Moreover, numerous recently pub-
lished data support the thesis that antimicrobial resis-
tance represents one of the major problems of modern
medicine (16, 17).
The problem of antimicrobial resistance attracts at-
tention of researchers worldwide. Literature data suggest
the existence of a strong correlation between bacterial re-
sistance properties and antibiotic consumption (3, 4, 18).
On the other hand, the amount of newly developed
antimicrobial agents that have recently been introduced
as therapeutic options for the treatment of bacterial in-
fections is limited. Therefore, alternative strategies for
the management of bacterial infections are inevitable.
Some of described strategies include changes in antibi-
otic administration policies, while some other include al-
ternative approaches to their management (19).
Bacteria of the genus Klebsiella are well known bacte-
rial pathogens that cause a wide variety of infections.
Some of these infections are life threatening, especially in
hospital settings. Numerous recent articles have reported
the growing trend of antimicrobial resistance among cli-
nical isolates of Klebsiella (20, 21). The emergence of
broad spectrum b-lactamases (AmpC) and extended spe-
ctrum b-lactamases (ESBL) among clinical isolates of
Klebsiella has resulted in limiting the number of thera-
peutic agents available. Therefore, alternative approaches
to prevention and/or therapy of Klebsiella infections seem
to be inevitable. In that regard, an anti-LPS monoclonal
antibody Ru-O1 was described previously to be protec-
tive in a model of lethal Klebsiella sepsis (7). The present
research was undertaken in order to reveal whether such
beneficial effect can be achieved in another experimental
model of lethal lung infection. Therefore, this study was
undertaken to establish a model of mice pneumonia
caused by intranasal bacterial challenge with K. pneu-
moniae Caroli. Similar models were described earlier
with several other bacterial pathogens (22, 23). This first
goal of the research was successfully reached and a model
of infection with LD50 value of only 50 CFU per mice
was established. Five times greater bacterial challenge re-
sulted in rapidly evolving infection with 100% lethality
and rapid bacterial dissemination from lungs throughout
the body within 24 hours after the infection. When ani-
mals were pretreated with anti-LPS mAb Ru-O1 four
hours prior to infection, 33% of animals survived the in-
fection with a lethal bacterial challenge, suggesting bene-
ficial effect of administered antibody. The explanation of
a lower degree of protection compared with the previous
results in a model of sepsis where it reaches 70%, may be
the fact that during the early stages of pulmonary infec-
tion, bacteria multiplied in lung tissue and then sud-
denly in a large number reached the blood and dissemi-
nated through animal organism. The mechanisms of
antibody action could not counteract such a large num-
ber of bacteria suddenly reaching bloodstream, which re-
sulted in lower survival rate. On the other hand, it may
be presumed that the lower survival rate may also be a
consequence of irreparable lung tissue damage. In con-
clusion, pretreatment of animals with anti-LPS mAb
was shown, although to a lesser extent to exert the protec-
tion in a mouse model of lethal Klebsiella lung infection.
The available literature data suggest the synergistic
activity of antibiotics and immunological preparations in
the treatment of various bacterial infections (24, 25). In
that regard, it was decided to test whether previously de-
scribed beneficial effect of mAb Ru-O1 in experimental
model of mice pneumonia caused by a highly virulent
strain of Klebsiella may be enhanced by administration of
a single dose of antibiotic. Therefore, a single therapeutic
dose of ceftazidime was applied 24 hours post infection.
The treatment of animals that were not pretreated with
mAb prior to infection resulted in survival of 33% of
mice. On the other hand, when antibiotic was adminis-
tered to animals that were pretreated with mAb, survival
rate rose to 66%. According to these results it can be con-
cluded that the administration of anti-LPS monoclonal
antibody in combination with a single dose of antibiotic
significantly enhances survival of lethally infected ani-
mals with pneumonia.
In conclusion, the results of the present study clearly
demonstrated the existence of synergism between antibi-
otic treatment and the monoclonal antibody used. Such
combined treatment of severe infections like pneumonia,
which was described in this paper, has two possible bene-
ficial effects. The first one is enhanced survival com-
pared to the treatment with each agent alone. The sec-
ond possible beneficial effect is, however, indirect. As
described before, the administration of a single dose of
antibiotic in animals pretreated with mAb resulted in
significantly increased survival of infected animals. The-
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refore, such combined treatment may influence the needs
for antibiotic consumption. As a consequence, this may
result in slowing down the negative trend of antibiotic re-
sistance development, but this assumption needs to be
supported by more extensive future studies.
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